240 related articles for article (PubMed ID: 38627362)
21. Review of bi-specific therapies in uveal melanoma.
Orloff M; Seedor R; Sato T
Cancer Gene Ther; 2022 Dec; 29(12):1814-1818. PubMed ID: 35236927
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.
Javed A; Arguello D; Johnston C; Gatalica Z; Terai M; Weight RM; Orloff M; Mastrangelo MJ; Sato T
Immunotherapy; 2017 Dec; 9(16):1323-1330. PubMed ID: 29185395
[TBL] [Abstract][Full Text] [Related]
23. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P
Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710
[TBL] [Abstract][Full Text] [Related]
24. Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma.
de Lange MJ; Nell RJ; Lalai RN; Versluis M; Jordanova ES; Luyten GPM; Jager MJ; van der Burg SH; Zoutman WH; van Hall T; van der Velden PA
Mol Cancer Res; 2018 Dec; 16(12):1902-1911. PubMed ID: 30093564
[TBL] [Abstract][Full Text] [Related]
25.
Hulen TM; Friese C; Kristensen NP; Granhøj JS; Borch TH; Peeters MJW; Donia M; Andersen MH; Hadrup SR; Svane IM; Met Ö
Front Immunol; 2023; 14():1180997. PubMed ID: 37359554
[TBL] [Abstract][Full Text] [Related]
26. Molecular profiling of driver events in metastatic uveal melanoma.
Karlsson J; Nilsson LM; Mitra S; Alsén S; Shelke GV; Sah VR; Forsberg EMV; Stierner U; All-Eriksson C; Einarsdottir B; Jespersen H; Ny L; Lindnér P; Larsson E; Olofsson Bagge R; Nilsson JA
Nat Commun; 2020 Apr; 11(1):1894. PubMed ID: 32313009
[TBL] [Abstract][Full Text] [Related]
27. Update on Metastatic Uveal Melanoma: Progress and Challenges.
Spagnolo F; Picasso V; Spano L; Tanda E; Venzano C; Queirolo P
BioDrugs; 2016 Jun; 30(3):161-72. PubMed ID: 27000042
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice.
Ma D; Niederkorn JY
Invest Ophthalmol Vis Sci; 1995 May; 36(6):1067-75. PubMed ID: 7730016
[TBL] [Abstract][Full Text] [Related]
29. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.
Mazzarella T; Cambiaghi V; Rizzo N; Pilla L; Parolini D; Orsenigo E; Colucci A; Modorati G; Doglioni C; Parmiani G; Maccalli C
Cancer Immunol Immunother; 2012 Aug; 61(8):1169-82. PubMed ID: 22207316
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of an immune and stromal prognostic signature in uveal melanoma to guide clinical therapy.
Gong Q; Wan Q; Li A; Yu Y; Ding X; Lin L; Qi X; Hu L
Aging (Albany NY); 2020 Oct; 12(20):20254-20267. PubMed ID: 33100273
[TBL] [Abstract][Full Text] [Related]
31. Epidrugs in the Immunotherapy of Cutaneous and Uveal Melanoma.
Venza M; Visalli M; Catalano T; Beninati C; Teti D; Venza I
Anticancer Agents Med Chem; 2017; 17(2):190-205. PubMed ID: 27109020
[TBL] [Abstract][Full Text] [Related]
32. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity.
Punt S; Malu S; McKenzie JA; Manrique SZ; Doorduijn EM; Mbofung RM; Williams L; Silverman DA; Ashkin EL; Dominguez AL; Wang Z; Chen JQ; Maiti SN; Tieu TN; Liu C; Xu C; Forget MA; Haymaker C; Khalili JS; Satani N; Muller F; Cooper LJN; Overwijk WW; Amaria RN; Bernatchez C; Heffernan TP; Peng W; Roszik J; Hwu P
Cancer Immunol Immunother; 2021 Apr; 70(4):1101-1113. PubMed ID: 33123754
[TBL] [Abstract][Full Text] [Related]
33. From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
Synoradzki KJ; Paduszyńska N; Solnik M; Toro MD; Bilmin K; Bylina E; Rutkowski P; Yousef YA; Bucolo C; Zweifel SA; Reibaldi M; Fiedorowicz M; Czarnecka AM
Curr Oncol; 2024 Feb; 31(2):778-800. PubMed ID: 38392052
[TBL] [Abstract][Full Text] [Related]
34. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
35. Dynamic Observation: Immune-Privileged Microenvironment Limited the Effectiveness of Immunotherapy in an Intraocular Metastasis Mouse Model.
Tao T; Liu Y; Zhang J; Huang L; Tao Y
Ophthalmic Res; 2022; 65(5):584-594. PubMed ID: 35398850
[TBL] [Abstract][Full Text] [Related]
36. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
[TBL] [Abstract][Full Text] [Related]
37. Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma.
Zoroquiain P; Esposito E; Logan P; Aldrees S; Dias AB; Mansure JJ; Santapau D; Garcia C; Saornil MA; Belfort Neto R; Burnier MN
Mod Pathol; 2018 Aug; 31(8):1201-1210. PubMed ID: 29581543
[TBL] [Abstract][Full Text] [Related]
38. Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options.
Brouwer NJ; Verdijk RM; Heegaard S; Marinkovic M; Esmaeli B; Jager MJ
Prog Retin Eye Res; 2022 Jan; 86():100971. PubMed ID: 34015548
[TBL] [Abstract][Full Text] [Related]
39. The Immunology of Melanoma.
Ko JS
Clin Lab Med; 2017 Sep; 37(3):449-471. PubMed ID: 28802495
[TBL] [Abstract][Full Text] [Related]
40. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
